Results 221 to 230 of about 30,774 (278)

Toward Monitoring and Addressing the Commercial Determinants of Health: Where Can We Go From Here? [PDF]

Milbank Q
Burgess R, Srebotnjak T, Lin C, Grierson L, Esty DC, Ransome Y, Freudenberg N.   +6 more
europepmc   +1 more source

Pharmacy Benefit Manager Market Concentration for Prescriptions Filled at Retail Pharmacies by State and Payer Type. [PDF]

JAMA Health Forum
Qato DM, Chen Y, Van Nuys K.
europepmc   +1 more source

Transfer and Survival of ST-Elevation Myocardial Infarction Medicare Patients. [PDF]

Cardiol Res
Leeberg M, Shermeyer A, Ward MJ, Virnig B, Wolfson J, Carroll C, Nikpay S.   +6 more
europepmc   +1 more source

Players' strategy selection in co-governance and supervision of internet platforms' monopolistic behaviors: A study on new media participation. [PDF]

PLoS One
Song Y, Xia T.
europepmc   +1 more source

Institutional Review Board Obligations Regarding Study Funding Sufficiency. [PDF]

Ethics Hum Res
Lynch HF, Mohammad T.
europepmc   +1 more source

REMS Logic Model: A Pragmatic Framework for Incorporating Drug Safety into Clinical Practice. [PDF]

Drug Saf
Toyserkani GA, Robottom SB, Morrato EH.
europepmc   +1 more source

Pharmaceutical industry antitrust handbook

, 2018
American Bar Association issuing body
core  

Financial Ties, Market Structure, Commercial Prices, and Medical Director Compensation in Dialysis.

JAMA Health Forum
Xia X, Deng W, Eliason PJ, League RJ, McDevitt RC, Roberts JW, Wong H.   +6 more
europepmc   +1 more source

Racist Antitrust, Antiracist Antitrust

The Antitrust Bulletin, 2021
If the tumultuous 2010s yielded one consistent theme, it is frustration with inequality coalescing into collective action. In response, progressive enforcers and commentators have begun to explore whether the antitrust laws—enacted in an attempt to counter concentrated power during a previous Gilded Age—might play a role in addressing systemic ...
Newman, John Mark
openaire   +2 more sources